Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
659 - As per the PAAB Code section 1.8 Definitions, the New Healthcare Product is defined as follow: "Any prescription or non-prescription product manufactured and/or marketed in Canada by a particular company for a period of less than 2 years". It is our understanding that for any APS we are limited to one year of usage of the word "New" from initial marketing. However, please clarify, what is the less than two years period in the above statement for the “New Healthcare Product" is referring to?
-
Please note that the complete definition for New Healthcare Products reads "Any prescription or non-prescription product manufactured and/or marketed in Canada by a particular company for a period of less than 2 years. Use of the word "new" or statements implying "new"; in advertising should be restricted to 1 year after initial marketing"; The portion relating to 2 years relates to a category threshold used by Health Canada for administrative purposes. It has no bearing on drug advertising. The 1 year provision comes from case law and is reflected in several codes and guidances within this industry and others.
